GENFIT: Updates to 2020 Financial Calendar
29 Avril 2020 - 10:15PM
GENFIT: Updates to 2020 Financial Calendar
- Publication of the Universal Registration Document and
Annual Report on Form 20-F are postponed until the end of May
2020
- All additional dates remain unchanged, including the
Annual Shareholders Meeting, scheduled for June 11,
2020.
Lille (France); Cambridge
(Massachusetts, United States) — April 29, 2020 —
GENFIT (Nasdaq and Euronext: GNFT), a late-stage
biopharmaceutical company dedicated to the discovery and
development of innovative therapeutic and diagnostic solutions in
metabolic and liver related diseases, today announced updates to
its financial calendar for 2020*. These changes are in response to
the current COVID-19 pandemic and organizational adjustments GENFIT
has implemented, as announced in a press release issued on March
31, 2020.
GENFIT’s efforts in coordinating its response to
the COVID-19 pandemic, especially those implemented for our
clinical trials, have mobilized the teams involved in the
preparation of the Universal Registration Document (“URD”) and the
Annual Report on Form 20-F (“Form 20-F”). These reports,
which were expected to be made available on April 30, 2020, will
now be made available one month later, at the end of May 2020.
Aside from the URD and Form 20-F publication
date, all other dates remain unchanged, and the 2020 financial
calendar is as follows:
May 18, 2020:
Publication of revenue and cash position as of March 31, 2020
End of May 2020:
Universal Registration Document and Form 20-F publication
June 11, 2020:
Annual Shareholders Meeting in Lille, FR
September 30,
2020:
Publication of the Half Year 2020 financial statements
November 16,
2020:
Publication of revenue and cash position as of September 30,
2020
* This calendar remains
tentative, and GENFIT reserves the right to amend the
aforementioned dates if necessary.
ABOUT GENFIT
GENFIT is a late-stage biopharmaceutical company
dedicated to the discovery and development of innovative
therapeutic and diagnostic solutions in metabolic and liver related
diseases where there are considerable unmet medical needs,
corresponding to a lack of approved treatments. GENFIT is a leader
in the field of nuclear receptor-based drug discovery, with a rich
history and strong scientific heritage spanning almost two decades.
Its most advanced drug candidate, elafibranor, is currently being
evaluated in a pivotal Phase 3 clinical trial (“RESOLVE-IT”) as a
potential treatment for NASH, and GENFIT plans to initiate a Phase
3 clinical trial of elafibranor in PBC. As part of GENFIT’s
comprehensive approach to clinical management of patients with
NASH, GENFIT is also developing a new, non-invasive blood-based
diagnostic test, NIS4, which, if approved, could enable easier
identification of patients with NASH. With facilities in Lille and
Paris, France, and Cambridge, MA, USA, the Company has
approximately 200 employees. GENFIT is a publicly traded company
listed on the Nasdaq Global Select Market and in compartment B of
Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT).
www.genfit.com
FORWARD LOOKING STATEMENTS
This press release contains certain
forward-looking statements, including those within the meaning of
the Private Securities Litigation Reform Act of 1995, with respect
to GENFIT, including forward-looking statements regarding its
financial calendar for 2020. The use of certain words, including
“believe,” “potential,” “expect” and “will” and similar
expressions, is intended to identify forward-looking
statements. Although GENFIT believes its expectations are
based on the current expectations and reasonable assumptions of the
Company’s management, these forward-looking statements are subject
to numerous known and unknown risks and uncertainties, which could
cause actual results to differ materially from those expressed in,
or implied or projected by, the forward-looking statements. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, biomarkers, progression of, and results from,
its ongoing and planned clinical trials, review and approvals by
regulatory authorities of its drug and diagnostic candidates and
the Company’s continued ability to raise capital to fund its
development, as well as those risks and uncertainties discussed or
identified in the Company’s public filings with the French Autorité
des marchés financiers (“AMF”), including those
listed in Section 4 “Main Risks and Uncertainties” of the Company’s
2018 Registration Document filed with the AMF on February 27, 2019
under n° D.19-0078, which is available on GENFIT’s website
(www.genfit.com) and on the website of the AMF (www.amf-france.org)
and public filings and reports filed with the U.S. Securities and
Exchange Commission (“SEC”), including GENFIT’s
final prospectus dated March 26, 2019, and subsequent filings and
reports filed with the AMF or SEC, or otherwise made public, by
GENFIT. In addition, even if GENFIT’s results, performance,
financial condition and liquidity, and the development of the
industry in which it operates are consistent with such
forward-looking statements, they may not be predictive of results
or developments in future periods. These forward-looking
statements speak only as of the date of publication of this
document. Other than as required by applicable law, the GENFIT does
not undertake any obligation to update or revise any
forward-looking information or statements, whether as a result of
new information, future events or otherwise.
CONTACT
GENFIT | Investors
Naomi EICHENBAUM – Investor Relations | Tel: +1
(617) 714 5252 | investors@genfit.com
PRESS RELATIONS | Media
Hélène LAVIN – Press relations | Tel: +333 2016
4000 | helene.lavin@genfit.com
GENFIT | 885 Avenue Eugène Avinée, 59120
Loos - FRANCE | +333 2016 4000 |
www.genfit.com
- GENFIT: Updates to 2020 Financial Calendar